Muscle Relaxant Drugs Market - By Drug Type (Skeletal Muscle Relaxant Drugs), Dosage Form (Tablet, Capsule), Application (Muscle Spasm & Pain Relief), Route of Administration (Oral), Distribution Channel (Hospital Pharmacy), Global Forecast 2023-2032

Muscle Relaxant Drugs Market Size

Muscle Relaxant Drugs Market size was valued to be USD 4.1 billion in 2022 and is expected to reach USD 9.4 billion in 2032 with a CAGR of 6.4% from 2023 to 2032. The market's significant growth is primarily driven by the rising geriatric population coupled with growing prevalence of chronic pain along with lower back pain.
 

For instance, in 2022, according to World Health Organization (WHO), the lower back pain affected nearly 619 million people globally and it is estimated that the number of cases will increase to 843 million cases by 2050. Therefore, patient awareness towards pain management drugs for the musculoskeletal r disorders along with the surge in drug discovery & development is expected to propel the growth of the market.
 

Muscle relaxant drugs, also known as muscle relaxants, are a class of drugs that are used to reduce muscle tension, stiffness, and spasms. They work by affecting the central nervous system or the muscle itself to alleviate discomfort and improve mobility in conditions associated with muscle-related issues. They are prescribed for various conditions such as neck, & low back pain, myofascial pain syndrome and fibromyalgia among other conditions. In addition, they are also used during surgical interventions along with general aesthetics for muscle relaxation.
 

COVID-19 Impact

The COVID-19 pandemic had a positive impact on muscle relaxant drugs market. The increased adoption of telemedicine and virtual consultations during the pandemic has led to greater awareness and education about various treatment options, including muscle relaxant drugs. Patients, especially those with musculoskeletal issues, have been more inclined to explore pharmaceutical solutions for managing their symptoms through remote medical guidance. Furthermore, the emphasis on maintaining overall well-being and addressing stress-related muscle tension during the pandemic has led to a heightened interest in approaches that promote relaxation and alleviate discomfort. This has potentially contributed to an increased demand for muscle relaxant drugs as people seek ways to manage physical discomfort caused by factors such as remote work, sedentary lifestyles, and stress.
 

Muscle Relaxant Drugs Market Driving Factors

Increasing global elderly population along with other medical condition is expected to spur the market growth. Aging commonly brings about diverse musculoskeletal concerns such as muscle stiffness, spasms, and discomfort. For example, as of 2021, the Global Burden of Disease (GBD) reported that, approximately 1.71 billion people worldwide are affected by musculoskeletal conditions. Thus, usage of muscle relaxant medications to alleviate these symptoms by diminishing muscle tension and inducing relaxation will augment the market growth. Furthermore, the market for muscle relaxant drugs is extended by factors including sports injuries, persistent pain among younger demographics, advancements in medical technologies, regulatory approvals, and evolving medical approaches.
 

Muscle Relaxant Drugs Market Restraint

While muscle relaxant drugs can offer significant benefits in managing muscle-related issues, they also come with potential side effects that can impact their market growth and usage. Several muscle relaxants have a sedative effect on the central nervous system, leading to drowsiness and reduced alertness, while some can cause dry mouth, which can be uncomfortable and lead to other oral health issues. In addition, muscle relaxant drugs can interact with other medications which the patient might be taking, leading to potential complications or reduced effectiveness. Therefore, owing to such potential side effects, prescribing muscle relaxant drugs requires careful consideration of the patient's medical history, current medications, and the potential risks versus benefits.
 

Muscle Relaxant Drugs Market Analysis

Based on the drug type, the muscle relaxant drugs market is segmented into skeletal muscle relaxant drugs, neuromuscular blocking agents, and facial muscle relaxant drugs. The skeletal muscle relaxant drugs segment held largest business share of 39% in 2022. Skeletal muscle relaxant drugs are commonly prescribed to manage conditions characterized by muscle spasms, cramps, stiffness, and other musculoskeletal disorders. These drugs work by reducing the intensity and frequency of contractions, providing relief to individuals suffering from muscular conditions. Also, the skeletal muscle relaxants can aid in the recovery phase by minimizing pain and muscle tension even undergoing surgical interventions. Therefore, the intricate and specialized demands of skeletal muscle relaxant drugs contribute to expand the market progress.
 

Based on the dosage form, the muscle relaxant drugs market is classified into tablet, capsule, liquid, and gel, ointments & sprays. The tablet segment led the global market in 2022, with a market size of USD 2 billion. This is owing to their inherent advantages that cater to the needs of both healthcare providers and patients. As tablets are one of the most common and familiar dosage forms, they allow for precise dosage control, making it easier for healthcare providers to prescribe specific amounts of the medication based on the patient's needs. Moreover, tablets offer a longer shelf life and enhanced stability compared to other forms, ensuring the drug's potency over time.
 

Based on the application, the muscle relaxant drugs market is fragmented into muscle spasm & pain relief, musculoskeletal disorders, surgery, and other applications. The muscle spasm & pain relief segment is expected to reach USD 4 billion by 2032. The muscle spasm and pain relief segment's prominence within the market is a result of the widespread need for efficient solutions to manage muscle-related discomfort. By alleviating muscle spasms and pain, these drugs improve patients' overall comfort, mobility, and ability to perform daily activities. They are often used as part of a comprehensive treatment plan that may include physical therapy, exercise, and lifestyle modifications, enhancing their effectiveness in providing relief.
 

Based on the route of administration, the muscle relaxant drugs market is divided into oral, parenteral, and topical. The oral route segment is expected to show significant growth of 6.2% during the analysis period. The dominance of the oral route within the market can be attributed to patient convenience, as they are accustomed to oral medication intake, making it an accepted and familiar approach. This familiarity contributes to higher adherence rates as patients are more likely to comply with prescribed treatment regimens. Also, the ease of administration associated with oral medications is a significant factor, as patients can self-administer without requiring specialized training or healthcare assistance.
 

Based on the distribution channel, the muscle relaxant drugs market is segmented into hospital pharmacy, specialty & retail pharmacy, and online pharmacy. The hospital pharmacy segment led the global market in 2022, with a market size of USD 2.3 billion. Hospital pharmacies play a crucial role in the market, as they are integral to the distribution, management, and administration of these medications within the healthcare ecosystem. Within hospital settings, muscle relaxant drugs are utilized to address a range of medical needs, from managing musculoskeletal pain and spasms to aiding in surgical procedures and critical care situations. Also, healthcare providers can collaborate with hospital pharmacies to ensure that appropriate muscle relaxants are administered based on individual patient conditions and treatment plans.
 

 In 2022, the North American muscle relaxant drugs market held the largest share of 37.6% and is anticipated to show considerable growth during the analysis period. musculoskeletal conditions, including muscle stiffness, spasms, and pain, are prevalent due to factors such as an aging population, sedentary lifestyles, and occupational stress. As a result, the demand for effective muscle relaxant drugs remains substantial. Moreover, the region's focus on quality healthcare and patient well-being drives the adoption of advanced treatment options, including pharmaceutical interventions like muscle relaxants. The region's emphasis on patient-centred care, along with the availability of telemedicine options, facilitates access to specialized medical advice and prescriptions, further driving the demand for muscle relaxants.
 

Muscle relaxant drugs Market Share

The prominent players in the muscle relaxant drugs market are

• Amneal Pharmaceuticals LLC
• Ipsen Biopharmaceuticals, Inc
• Merz Pharmaceuticals, LLC
• Mylan (Viatris)
• Sanofi
• Pfizer Inc
• Novartis AG
• eva Pharmaceuticals Industries Ltd, Inc
• Vertical Pharmaceuticals
• Sun Pharmaceutical Industries Ltd
• SteriMax Inc
• Par Pharmaceutical
• Abbott Laboratories
• F. Hoffmann-La Roche AG

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
 

Muscle relaxant drugs Industry News:

• In June 2022, Amneal Pharmaceuticals launched LYVISPAH, a baclofen oral granules specialty product approved by the U.S. FDA for treating spasticity associated to multiple sclerosis and other spinal cord disorders. This helped the company in expanding its product portfolio and generate maximum revenue from its sales.


• In January 2022, Amneal Pharmaceuticals purchased Saol's Baclofen franchise, containing Lioresal and LYVISPAH, and a pipeline product under development. The acquisition enlarged the company's commercial institutional and specialty portfolio in neuromuscular segment and helped in the growth of the market.
   

The muscle relaxant drugs market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Drug Type

• Skeletal muscle relaxant drugs
• Neuromuscular blocking agents
• Facial muscle relaxant drugs

By Dosage Form

• Tablet
• Capsule
• Liquid
• Gel, ointments & sprays

By Application

• Muscle spasm & pain relief
• Musculoskeletal disorders
• Surgery
• Other applications

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital pharmacy
• Specialty & retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa 
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa